{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-24-003209","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.234081+00:00","generated_at":"2026-05-31T14:33:24.646758+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cadrenal stockholders approve reverse split, share increase, and equity plan amendment","bullets":["Approved reverse stock split at Board's discretion (1:2 to 1:20 ratio).","Authorized share increase from 75M to 125M shares of common stock.","Equity plan amendment adds 2,000,000 shares (total 4,604,550) and modifies evergreen provision to 20% of outstanding plus warrant shares.","Elected directors John Murphy and Robert Lisicki to Class II until 2027.","Ratified WithumSmith+Brown as independent auditor for 2024 fiscal year."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-24-003209","json":"https://secwatch.observer/filing/0001013762-24-003209.json","markdown":"https://secwatch.observer/filing/0001013762-24-003209.md","text":"https://secwatch.observer/filing/0001013762-24-003209.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000101376224003209/0001013762-24-003209-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000101376224003209/ea0210326-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:33:24.646758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}